Extraordinary Science
Life-Changing Therapies

About DHX9

Accent’s lead program is a first-in-class DHX9 inhibitor with the potential to address high unmet need indications that lack targeted therapies, including high microsatellite instable (MSI-H) cancers. This program is advancing rapidly, with a drug candidate nomination expected in the second half of 2023. DHX9 is an RNA helicase that has been reported to play important roles in replication, transcription, translation, RNA splicing, RNA processing, and maintenance of genomic stability. Overexpression of DHX9 is observed in multiple cancer types making this helicase a compelling novel oncology target.

About ADAR1

Accent is developing ADAR1 targeted therapies to address many solid tumor indications with significant unmet need as monotherapy, including non-small cell lung cancer, triple-negative breast cancer, ovarian cancer, and head and neck squamous cell carcinomas. Data also suggests that small molecule inhibitors of ADAR1 have further potential to combine well with checkpoint inhibitors, to treat PD1 and PD-L1 relapse/refractory tumors.

In tumor cells with higher IFN signaling, small molecule inhibitors of ADAR1 induce selective cell killing and immune sensitization, making it a highly attractive target for monotherapy and in combination with immuno-oncology therapy.